Varicella vaccination in HIV-1-infected children after immune reconstitution

AIDS

Volumn 20, Issue 18, 2006, Pages 2321-2329

  Bekker, Vincent ^a   Westerlaken, Geertje H A ^a,b   Scherpbier, Henriëtte ^a   Alders, Sophie ^a   Zaaijer, Hans ^a   Van Baarle, Debbie ^a,b   Kuijpers, Taco ^a,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c EMMA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Children; HIV 1 infection; Immunology; Vaccination; Varicella zoster virus

Indexed keywords

CD4 ANTIGEN; CHICKENPOX VACCINE; IMMUNOGLOBULIN G ANTIBODY; LIVE VACCINE; VIRUS ANTIBODY;

ABSENCE OF SIDE EFFECTS; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHICKENPOX; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNIZATION; LYMPHOCYTE COUNT; MALE; NETHERLANDS; PRIORITY JOURNAL; SIBLING; SYMPTOM; VACCINATION; VARICELLA ZOSTER VIRUS;

ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CHICKENPOX; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HERPESVIRUS 3, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE COUNT; MALE; RISK FACTORS; SIBLINGS; T-LYMPHOCYTES; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 33751222547     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280113f29     Document Type: Article

References (30)

1. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996; 9:361-381.
2. Strauss JH, Strauss EG, editors. DNA-containing viruses. San Diego, California: Elvevier; 2002. pp. 221-277.
3. Kuijpers TW, Vossen MT, Gent MR, Davin JC, Roos MT, Wertheim-van Dillen PM, et al. Frequencies of circulating cytolytic, CD45RA+CD27-, CD8+ T lymphocytes depend on infection with CMV. J Immunol 2003; 170:4342-4348.
4. Lee BW. Review of varicella zoster seroepidemiology in India and Southeast Asia. Trop Med Int Health 1998; 3:886-890.
5. Preblud SR. Age-specific risks of varicella complications. Pediatrics 1981; 68:14-17.
6. Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics 1986; 78:748-756.
7. Diaz PS, Smith S, Hunter E, Arvin AM. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol 1989; 142:636-641.
8. Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. Development of virus-specific CD4+T cells on reexposure to varicella-zoster virus. J Infect Dis 2004; 190:72-82.
9. Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360:678-682.
10. von Seidlein L, Gillette SG, Bryson Y, Frederick T, Mascola L, Church J, et al. Frequent recurrence and persistence of varicella-zoster virus infections in children infected with human immunodeficiency virus type 1. J Pediatr 1996; 128:52-57.
11. Winquist AG, Roome A, Hadler J. Varicella outbreak at a summer camp for human immunodeficiency virus-infected children. Pediatrics 2001; 107:67-72.
12. Glesby MJ, Hoover DR, Tan T, Shi Q, Gao W, French AL, et al. Herpes zoster in women with and at risk for HIV: data from the women's interagency HIV study. J Acquir Immune Defic Syndr 2004; 37:1604-1609.
13. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaaijer H, Kuijpers TW. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatrics 2006; 118:e315-e322.
14. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974; 304:1288-1290.
15. Centers for Disease Control and Prevention. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999; 48:1-5.
16. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Official authorized addenda: human immunodeficiency virus infection codes and official guidelines for coding and reporting ICD-9-CM. MMWR 1994; 43:1-19.
17. Levin MJ, Gershon AA, Weinberg A, Blanchard S, Nowak B, Palumbo P, Chan Y. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001; 139:305-310.
18. Dunn D. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362:1605-1611.
19. Abrams EJ, Weedon J, Steketee RW, Lambert G, Bamji M, Brown T, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998; 178:101-108.
20. Shearer WT, Quinn TC, LaRussa P, Lew JF, Mofenson L, Almy S, et al. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. Women and Infants Transmission Study Group. N Engl J Med 1997; 336:1337-1342.
21. Alkhatib G, Combadiere C, Broder CC, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958.
22. Juffermans NP, Paxton WA, Dekkers PEP, Bergon A, de Jonge E, Speelman P, et al. Up-regulation of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells during human endotoxemia and after stimulation with (myco)bacterial antigens: the role of cytokines. Blood 2000; 96:2649-2654.
23. Vossen MTM, Biezeveld MH, de Jong MD, Gent M-R, Baars PA, von Rosenstiel IA, et al. Absence of circulating natural killer and primed CD8+ cells in life-threatening varicella. J Infect Dis 2005; 191:198-206.
24. van der Zwet WC, Vandenbroucke-Grauls CM, van Elburg RM, Cranendonk A, Zaaijer HL. Neonatal antibody titers against varicella-zoster virus in relation to gestational age, birth weight, and maternal titer. Pediatrics 2002; 109:79-85.
25. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004; 23:132-137.
26. Gershon AA, Steinberg SP. Cellular and humoral immune responses to varicella-zoster virus in immunocompromised patients during and after varicella-zoster infections. Infect Immun 1979; 25:170-174.
27. Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis 2002; 34:774-779.
28. Krause PR, Klinman DM. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat Med 2000; 6:451-454.
29. Moir S, Ogwaro KM, Malaspina A, Vasquez J, Donaghue ET, Hallahan CW, et al. Perturbations in B cell responsiveness to CD4+ T cell help in HIV-infected individuals. Proc Natl Acad Sci U S A 2003; 100:6057-6062.
30. Moir S, Malaspina A, Ogwaro KM, Donoghue ET, Hallahan CW, Ehler LA, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci U S A 2001; 98:10362-10367.